Literature DB >> 6402002

Effects of valinomycin, A23187 and repetitive sickling on irreversible sickle cell formation.

M P Westerman, D Allan.   

Abstract

The formation of irreversibly sickled red cells has been studied by inducing cell shrinkage, ion loss, Ca2+ accumulation and membrane loss either singly or in combination. Valinomycin, A23187+Ca2+ or hypertonic saline caused shrinkage of the cells with retention of the sickled form after reoxygenation. The cells which had retained the sickle shape after treatment with the ionophores and reoxygenation remained sickled after exposure to hypotonic media. These cells were also osmotically insensitive. Retention of the sickled form was not dependent upon membrane loss as induced by repeated sickle-unsickle cycles or by A23187+Ca2+ treatment although repetitive sickling did give rise to shorter, stubbier spicules. Sickled red cells, either the endogenous irreversibly sickled cells or the sickled cells induced by deoxygenation, did not lose membrane by vesicle or spicule loss as normal cells or oxygenated sickle red cells do. Cell water loss without cell membrane loss appears to be an important factor in the irreversible sickling of red cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402002     DOI: 10.1111/j.1365-2141.1983.tb02040.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Implementation of Indigenous Electronic Medical Record System to Facilitate Care of Sickle Cell Disease Patients in Chhattisgarh.

Authors:  Mona Choubey; Hrishikesh Mishra; Khushboo Soni; Pradeep Kumar Patra
Journal:  J Clin Diagn Res       Date:  2016-02-01

2.  Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells.

Authors:  P F Franck; E M Bevers; B H Lubin; P Comfurius; D T Chiu; J A Op den Kamp; R F Zwaal; L L van Deenen; B Roelofsen
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.